磺达肝癸钠用于治疗非ST段抬高急性冠脉综合征的临床观察  

Clinical Evaluation of Fondaparinux Na in Treating Non-ST Elevation Acute Coronary Syndrome

作　　者：侯小路[1] 王方[2] 白秀萍[1] 

机构地区：[1]哈尔滨医科大学附属第四医院心内科,哈尔滨150001 [2]内蒙古自治区呼和浩特市武警内蒙古总队医院内二科

出　　处：《血栓与止血学》2010年第5期219-221,共3页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的观察磺达肝癸钠治疗非ST段抬高急性冠脉综合征的临床疗效及安全性。方法非ST段抬高急性冠脉综合征患者162例,随机分为对照组(80例)和治疗组(82例),两组基础治疗相同。对照组除基础治疗外,给予低相对分子质量肝素5000u,皮下注射,每12h1次,连用7d。治疗组除基础治疗外,给予磺达肝癸钠2.5mg/d皮下注射,连用7d。观察治疗30d内心脏事件发生情况。结果治疗组心绞痛、Q波心肌梗死、死亡、急性冠脉介入治疗、出血并发症例数均较对照组明显减少(P<0.05)。结论磺达肝癸钠治疗非ST段抬高急性冠脉综合征安全有效。Objective To observe the clinical value and security of non-ST-segment elevation acute cornary syndrome （ NSTE- ACS） by using fondaparinux Na. Methods 162 patients with （ NSTE- ACS） were selected and randomly divided into control group （80 cases） and treatment group （82 cases）. Besides the basic treatment, 5 000 u low molecular weight heparin was administrated to the control group subcutaneously every 12 hours for 7 days. The treatment group were given fondaparinux- Na 2.5 mg per day subcutaneously for 7 days. Occurrences of cardiac disease were observed for 30 days. Results Occurrences of angina, Q-type cardiac infarct, acute coronary interventional therapy, hemorrhage of the treatment group were obvious less than the control group （ P 〈 0.05 ）. Conclusion Fondaparinux Na was a safe and effective treatment for NSTEMI.

关 键 词：磺达肝癸钠 非ST段抬高急性冠脉综合征 

分 类 号：R541.4[医药卫生—心血管疾病]